Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia CorpfiledCriticalPharmacia Corp
Publication of TW200501937ApublicationCriticalpatent/TW200501937A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an anti-diabetic sgent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred anti-diabetic agents are those compounds having high potency and oral or parenteral bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α ,11α-substituted epoxy moiety.
TW093106121A2003-03-142004-03-09Combination of an aldosterone receptor antagonist and an anti-diabetic agent
TW200501937A
(en)
Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds